| [1] |
Bratan F, Niaf E, Melodelima C, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study[J]. Eur Radiol, 2013, 23(7): 2019-2029.
|
| [2] |
Le JD, Tan N, Shkolyar E, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology[J]. Eur Urol, 2015, 67(3): 569-576.
|
| [3] |
Borofsky S, George AK, Gaur S, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate[J]. Radiology, 2018, 286(1): 186-195.
|
| [4] |
Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive (68)ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis[J]. Eur Urol, 2016,70(6):926-937.
|
| [5] |
Briganti A, Passoni N, Ferrari M, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool[J]. Eur Urol, 2010, 57(4): 551-558.
|
| [6] |
Rouviere O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study[J]. Lancet Oncol, 2019, 20(1): 100-109.
|
| [7] |
van der Leest M, Cornel E, Israel B, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen: a large prospective multicenter clinical study[J]. Eur Urol, 2019, 75(4): 570-578.
|
| [8] |
Cornud F, Roumiguie M, Barry DLN, et al. Precision matters in mr imaging-targeted prostate biopsies: evidence from a prospective study of cognitive and elastic fusion registration transrectal biopsies[J]. Radiology, 2018, 287(2): 534-542.
|
| [9] |
Bryk DJ, Llukani E, Taneja SS, et al. The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy[J]. Urology, 2017, 102: 178-182.
|
| [10] |
Ploussard G, Staerman F, Pierrevelcin J, et al. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy[J]. J Urol, 2013, 190(5): 1750-1756.
|
| [11] |
Wiegel T, Bartkowiak D, Bottke D, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial[J]. Int J Radiat Oncol Biol Phys, 2015, 91(2): 288-294.
|
| [12] |
Moreira DM, Presti JJ, Aronson WJ, et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database[J]. BJU Int, 2010, 105(11): 1541-1547.
|
| [13] |
Eiber M, Herrmann K, Fendler WP, et al. (68)Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-Early or Too Early to Draw Conclusions?[J]. Eur Urol, 2016,70(6): 938-940.
|
| [14] |
Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?[J]. Eur J Nucl Med Mol Imaging, 2015, 42(8): 1284-1294.
|
| [15] |
Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18f-fluoromethylcholine versus 68ga-psma pet/ct in prostate cancer patients who have rising psa after curative treatment and are being considered for targeted therapy[J]. J Nucl Med, 2015, 56(8): 1185-1190.
|
| [16] |
van Leeuwen PJ, Stricker P, Hruby G, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment[J]. BJU Int, 2016, 117(5): 732-739.
|
| [17] |
Sanli Y, Kuyumcu S, Sanli O, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer[J]. Ann Nucl Med, 2017, 31(9): 709-717.
|
| [18] |
Mena E, Lindenberg ML, Shih JH, et al. Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy[J]. Eur J Nucl Med Mol Imaging, 2018, 45(1): 4-11.
|
| [19] |
Habl G, Sauter K, Schiller K, et al. (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment[J]. Prostate, 2017, 77(8): 920-927.
|
| [20] |
Amling CL, Bergstralh E J, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?[J]. J Urol, 2001, 165(4): 1146-1151.
|
| [21] |
Stephenson AJ, Kattan MW, Eastham J A, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition[J]. J Clin Oncol, 2006, 24(24): 3973-3978.
|
| [22] |
Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience[J]. J Urol, 2007, 178(6): 2359-2365.
|
| [23] |
Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer[J]. N Engl J Med, 2014, 370(10): 932-942.
|
| [24] |
Ilic D, Evans SM, Allan CA, et al. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer[J]. Cochrane Database Syst Rev, 2017, 9: D9625.
|
| [25] |
Fossati N, Willemse PM, Van den Broeck T, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review[J]. Eur Urol, 2017, 72(1): 84-109.
|
| [26] |
Valerio M, Cerantola Y, Eggener SE, et al. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review[J]. Eur Urol, 2017, 71(1): 17-34.
|
| [27] |
周祥福. 2018版欧洲泌尿外科前列腺癌指南要点解读[J]. 中华腔镜泌尿外科杂志（电子版）, 2018, 12(5): 289-294.
|
| [28] |
Sweeney CJ, hen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.N Engl J Med, 2015, 373(8): 737-746.
|
| [29] |
Small E J, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer[J]. Ann Oncol, 2019.
|
| [30] |
Shore N, Zurth C, Fricke R, et al. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial[J]. Target Oncol, 2019.
|
| [31] |
Moreira DM, Presti JJ, Aronson WJ, et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database[J]. BJU Int, 2010, 105(11): 1541-1547.
|
| [32] |
Moreira DM, Presti JJ, Aronson WJ, et al. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database[J]. J Urol, 2009, 182(5): 2250-2255.
|